Business Description
Chromocell Therapeutics Corp
NAICS : 541713
SIC : 8731
ISIN : US1711261057
Description
Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.97 | |||||
| Equity-to-Asset | 0.28 | |||||
| Debt-to-Equity | 1.12 | |||||
| Debt-to-EBITDA | -0.16 | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -155.9 | |||||
| 3-Year EPS without NRI Growth Rate | -106.2 | |||||
| 3-Year FCF Growth Rate | 24.2 | |||||
| 3-Year Book Growth Rate | -42.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 24.54 | |||||
| 9-Day RSI | 34.76 | |||||
| 14-Day RSI | 38.06 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.39 | |||||
| Quick Ratio | 1.39 | |||||
| Cash Ratio | 1.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 14.7 | |||||
| Shareholder Yield % | -67.6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 8.47 | |||||
| Price-to-Tangible-Book | 7.1 | |||||
| EV-to-EBIT | -1.36 | |||||
| EV-to-EBITDA | -1.36 | |||||
| EV-to-FCF | -3.84 | |||||
| Price-to-Net-Current-Asset-Value | 7.1 | |||||
| Price-to-Net-Cash | 9.47 | |||||
| Earnings Yield (Greenblatt) % | -73.53 | |||||
| FCF Yield % | -29.25 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:CHRO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Chromocell Therapeutics Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.662 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 38.06 | ||
| 14-Day ATR ($) | 0.305404 | ||
| 20-Day SMA ($) | 1.823355 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 1.21 - 6 | ||
| Shares Outstanding (Mil) | 5.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Chromocell Therapeutics Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Chromocell Therapeutics Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Chromocell Therapeutics Corp Frequently Asked Questions
What is Chromocell Therapeutics Corp(CHRO)'s stock price today?
The current price of CHRO is $1.42. The 52 week high of CHRO is $6.00 and 52 week low is $1.21.
When is next earnings date of Chromocell Therapeutics Corp(CHRO)?
The next earnings date of Chromocell Therapeutics Corp(CHRO) is .
Does Chromocell Therapeutics Corp(CHRO) pay dividends? If so, how much?
Chromocell Therapeutics Corp(CHRO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers